Compare CABA & DSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABA | DSP |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.7M | 213.3M |
| IPO Year | 2019 | 2021 |
| Metric | CABA | DSP |
|---|---|---|
| Price | $3.63 | $9.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $14.57 | ★ $18.50 |
| AVG Volume (30 Days) | ★ 3.0M | 182.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 160.87 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $289,235,000.00 |
| Revenue This Year | N/A | $17.79 |
| Revenue Next Year | N/A | $17.72 |
| P/E Ratio | ★ N/A | $93.83 |
| Revenue Growth | N/A | ★ 29.74 |
| 52 Week Low | $0.99 | $8.11 |
| 52 Week High | $3.78 | $21.03 |
| Indicator | CABA | DSP |
|---|---|---|
| Relative Strength Index (RSI) | 71.51 | 36.45 |
| Support Level | $2.11 | $9.20 |
| Resistance Level | N/A | $9.50 |
| Average True Range (ATR) | 0.26 | 0.57 |
| MACD | 0.07 | -0.09 |
| Stochastic Oscillator | 98.94 | 26.34 |
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.